Increasing Benefit From Revascularization Is Associated With Increasing Amounts of Myocardial Hibernation. A Substudy of the PARR-2 Trial

JACC: Cardiovascular Imaging

Volumn 2, Issue 9, 2009, Pages 1060-1068

  D'Egidio, Gianni ^a   Nichol, Graham ^b   Williams, Kathryn A ^a   Guo, Ann ^a   Garrard, Linda ^a   deKemp, Robert ^a   Ruddy, Terrence D ^a   DaSilva, Jean ^a   Humen, Dennis ^c   Gulenchyn, Karen Y ^d   Freeman, Michael ^e   Racine, Normand ^f   Benard, Francois ^g   Hendry, Paul ^a   Beanlands, Rob S B ^a  

^a National Cardiac PET Centre   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d Divisions of Cardiology   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

fluorodeoxyglucose; heart failure; ischemic heart disease; viability

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUORODEOXYGLUCOSE F 18; NITRATE;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATION; DISEASE SEVERITY; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MYOCARDIAL HIBERNATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

AGED; CORONARY ARTERY DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; MYOCARDIAL STUNNING; MYOCARDIUM; PATIENT READMISSION; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TISSUE SURVIVAL; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70149114097     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2009.02.017     Document Type: Article

References (26)

1. Kron I.L., Flanagan T.L., Blackbourne L.H., Schroeder R.A., and Nolan S.P. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 210 (1989) 348-352
2. Tjan T., Kondruweit M., Scheld H., et al. The bad ventricle-revascularization versus transplantation. Thorac Cardiovasc Surg 48 (2000) 9-14
3. Jones R. Is it time for a randomized trial of surgical treatment of ischemic heart failure?. J Am Coll Cardiol (2001) 1210-1213
4. Di Carli M.F., Davidson M., Little R., et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 73 (1994) 527-533
5. Louie H.W., Laks H., Milgalter E., et al. Ischemic cardiomyopathy. Criteria for myocardial revascularization and cardiac transplantation. Circulation 84 Suppl (1991) III290-III295
6. Hochberg M.S., Parsonnet V., Gielchiisky I., and Hussain S.M. Coronary artery bypass grafting in patients with ejection fraction below forty percent. J Thorac Cardiovasc Surg 86 (1983) 519-525
7. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., and Rahimtoola S.H. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 32 (2007) 375-410
8. Eitzman D., Al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 20 (1992) 559-565
9. Lee K.S., Marwick T.H., Cook S.A., et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: relative efficacy of medical therapy and revascularization. Circulation 90 (1995) 2687-2694
10. Haas F., Haehnel C.J., Picker W., Nekolla S., Martinoff S., Meisner H., and Schwaiger M. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 30 (1997) 1693-1700
11. Zhang X., Liu X.J., Wu Q., et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med 42 (2001) 1166-1173
12. Yoshida K., and Gould K.L. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 22 (1993) 984-997
13. vom Dahl J., Altehoefer C., Sheehan F.H., et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 38 (1997) 742-748
14. Desideri A., Cortigiani L., Christen A., et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 46 (2005) 1264-1269
15. Di Carli M.F., Maddahi J., Rokhsar S., et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 116 (1998) 997-1004
16. Pagano D., Lewis M.E., Townend J.N., Davies P., Camici P.G., and Bonser R.S. Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival. Heart 82 (1999) 684-688
17. Bax J.J., Visser F.C., Poldermans D., et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 104 Suppl 1 (2001) I314-I318
18. Allman K.C., Shaw L., Hachamovitch R., and Udelson J. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
19. Beanlands R., Nichol G., Huszti E., et al. F-18-Fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease (PARR-2). J Am Coll Cardiol 50 (2007) 2002-2012
20. Beanlands R., Nichol G., and Ruddy T.D. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Control Clin Trials 24 (2003) 776-794
21. Beanlands R.S., Ruddy T.D., deKemp R.A., et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 40 (2002) 1735-1743
22. Machac J., Bacharach S.L., Bateman T.M., et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 13 (2006) e121-e151
23. Vitale G.D., deKemp R.A., Ruddy T.D., Williams K., and Beanlands R.S. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 42 (2001) 1730-1736
24. Zipes D.P., Camm A.J., Borggrefe M., et al., European Heart Rhythm Association; Heart Rhythm Society; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48 (2006) e247-e346
25. Issa N., Poggio E.D., Fatica R.A., Patel R., Ruggieri P.M., and Heyka R.J. Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI. Cleve Clin J Med 75 (2008) 95-97 103-4,106
26. Feldkamp T., and Kribben A. Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. Minerva Med 99 (2008) 177-196